Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology without MYCN Amplification.

5-year EFS/OS for patients treated with high-risk therapy on A3973 and ANBL0532 were 73.0±8.1%/87.9±5.9% and 61.4±10.2%/73.0±9.2%, respectively (p=0.1286 and p=0.2180). In the A3973/ANBL0532 cohort, patients with CONCLUSION: Patients ≥18 months of age at diagnosis who had tumors with UH and MYCN-NA INSS Stage 3 neuroblastoma assigned to high-risk therapy had an 81.6±5.3% 5-year OS. Less than PR to induction therapy and chromosome 11q loss/LOH are independent predictors of inferior outcome and identify patients who should be eligible for future high-risk clinical trials.